KR20210104079A - 항-trem2 항체를 사용하는 방법 - Google Patents

항-trem2 항체를 사용하는 방법 Download PDF

Info

Publication number
KR20210104079A
KR20210104079A KR1020217021577A KR20217021577A KR20210104079A KR 20210104079 A KR20210104079 A KR 20210104079A KR 1020217021577 A KR1020217021577 A KR 1020217021577A KR 20217021577 A KR20217021577 A KR 20217021577A KR 20210104079 A KR20210104079 A KR 20210104079A
Authority
KR
South Korea
Prior art keywords
antibody
seq
trem2
cdr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217021577A
Other languages
English (en)
Korean (ko)
Inventor
미셸 스트레울리
레너드 지. 프리스타
벤카타라만 스리람
아리트라 팔
나딘 자찬
미하일 비네비스
조슈아 엘. 폴락
샤오얀 두
Original Assignee
파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/065026 external-priority patent/WO2019118513A1/en
Application filed by 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 filed Critical 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드
Publication of KR20210104079A publication Critical patent/KR20210104079A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217021577A 2018-12-11 2019-12-11 항-trem2 항체를 사용하는 방법 Ceased KR20210104079A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2018/065026 WO2019118513A1 (en) 2017-12-12 2018-12-11 Anti-trem2 antibodies and related methods
USPCT/US2018/065026 2018-12-11
US201962889990P 2019-08-21 2019-08-21
US62/889,990 2019-08-21
PCT/US2019/065743 WO2020123664A1 (en) 2018-12-11 2019-12-11 Methods of using anti-trem2 antibodies

Publications (1)

Publication Number Publication Date
KR20210104079A true KR20210104079A (ko) 2021-08-24

Family

ID=71076653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217021577A Ceased KR20210104079A (ko) 2018-12-11 2019-12-11 항-trem2 항체를 사용하는 방법

Country Status (8)

Country Link
US (1) US20210317211A1 (https=)
EP (1) EP3893931A4 (https=)
JP (2) JP7688579B2 (https=)
KR (1) KR20210104079A (https=)
CN (1) CN113194994B (https=)
AU (1) AU2019397479A1 (https=)
CA (1) CA3120875A1 (https=)
WO (1) WO2020123664A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2019118513A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
PH12021552002A1 (en) 2019-02-20 2022-09-19 Denali Therapeutics Inc Anti-trem2 antibodies and methods of use thereof
PE20221465A1 (es) 2020-01-13 2022-09-21 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
WO2024250809A1 (zh) * 2023-06-08 2024-12-12 成都优洛生物科技有限公司 抗trem2全人源抗体或其抗原结合片段及其应用
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
CN119775421B (zh) * 2023-12-21 2025-10-31 华润生物医药有限公司 抗trem2抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311487D0 (en) * 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
EP3177322A4 (en) 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
JP2019516362A (ja) * 2016-04-27 2019-06-20 ファイザー・インク 抗ｉｌ−３３抗体、その組成物、方法および使用
WO2019118513A1 (en) * 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods

Also Published As

Publication number Publication date
JP2025128164A (ja) 2025-09-02
JP2022514734A (ja) 2022-02-15
EP3893931A1 (en) 2021-10-20
WO2020123664A1 (en) 2020-06-18
CN113194994B (zh) 2025-11-28
EP3893931A4 (en) 2022-09-07
CN113194994A (zh) 2021-07-30
CA3120875A1 (en) 2020-06-18
AU2019397479A1 (en) 2021-07-29
JP7688579B2 (ja) 2025-06-04
US20210317211A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
US12428481B2 (en) Anti-TREM2 antibodies and related methods
JP7688579B2 (ja) 抗ｔｒｅｍ２抗体の使用方法
US20250179185A1 (en) Anti-trem1 antibodies and related methods
KR20240111798A (ko) 항-trem2 항체를 사용한 섬유증 치료
US12065491B2 (en) Anti-TREM1 antibodies and related methods
HK40037160A (en) Anti-trem2 antibodies and related methods
HK40037160B (zh) 抗trem2抗体和相关方法
HK40065337A (en) Anti-trem1 antibodies and related methods

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601